- Home
- NDSN vs MRNA Comparison
NDSN vs MRNA Comparison
Compare NDSN & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDSN
- MRNA
- Stock Information
- Founded
- NDSN 1935
- MRNA 2010
- Country
- NDSN United States
- MRNA United States
- Employees
- NDSN N/A
- MRNA N/A
- Industry
- NDSN Industrial Machinery/Components
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NDSN Industrials
- MRNA Health Care
- Exchange
- NDSN Nasdaq
- MRNA Nasdaq
- Market Cap
- NDSN 14.5B
- MRNA 16.5B
- IPO Year
- NDSN N/A
- MRNA 2018
- Fundamental
- Price
- NDSN $261.27
- MRNA $41.11
- Analyst Decision
- NDSN Strong Buy
- MRNA Hold
- Analyst Count
- NDSN 5
- MRNA 17
- Target Price
- NDSN $303.00
- MRNA $83.00
- AVG Volume (30 Days)
- NDSN 211.8K
- MRNA 10.0M
- Earning Date
- NDSN 12-11-2024
- MRNA 11-07-2024
- Dividend Yield
- NDSN 1.19%
- MRNA N/A
- EPS Growth
- NDSN N/A
- MRNA N/A
- EPS
- NDSN 8.21
- MRNA N/A
- Revenue
- NDSN $2,664,752,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- NDSN $4.12
- MRNA N/A
- Revenue Next Year
- NDSN $9.32
- MRNA N/A
- P/E Ratio
- NDSN $31.82
- MRNA N/A
- Revenue Growth
- NDSN 2.77
- MRNA N/A
- 52 Week Low
- NDSN $222.18
- MRNA $35.80
- 52 Week High
- NDSN $279.38
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- NDSN 58.74
- MRNA 34.85
- Support Level
- NDSN $248.28
- MRNA $35.96
- Resistance Level
- NDSN $259.51
- MRNA $39.77
- Average True Range (ATR)
- NDSN 4.61
- MRNA 3.27
- MACD
- NDSN 0.13
- MRNA -0.17
- Stochastic Oscillator
- NDSN 74.65
- MRNA 25.41
About NDSN Nordson Corporation
Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.6 billion in revenue in its fiscal 2023.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.